You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歐康維視生物-B(01477.HK)OT-703新藥臨床III期申請獲批
阿思達克 06-09 18:02
歐康維視生物-B(01477.HK)公布,OT-703(氟輕鬆玻璃體植入劑)的新藥臨床試驗申請已獲中國國家藥品監督管理局藥品審評中心批准,以在中國開展一項隨機、雙盲、平行對照、多中心III期臨床試驗。 集團表示,OT-703為一種可注射的、非生物降解的氟輕鬆玻璃體植入劑,用於治療糖尿病性黃斑水腫(DME)。此項III期臨床試驗旨在對比0.19毫克氟輕鬆玻璃體植入劑與雷珠單抗注射液治療DME的安全性和有效性。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account